Research promising for cystic fibrosis

New University of Toronto research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus.

Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS). One of these compounds, exosin, significantly inhibited infections in mammalian cells, showing promise for increasing the effectiveness of antibiotics in the treatment of chronic and acute bacterial respiratory infections in cystic fibrosis patients.

Past studies have shown it is possible to prevent or delay the onset of certain chronic or deadly infections in cystic fibrosis patients with early antibiotic treatment. But the current availability of antibiotics against Pseudomonas aeruginosa, a pathogen that can cause urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections, is limited and the pathogen shows signs of drug resistance.

In an article published in the online edition of the journal PLoS Genetics, a team of investigators, including first author and U of T graduate student Anthony Arnoldo, identified several drugs that block a Pseudomonas aeruginosa toxin called ExoS.

"These studies created a road map to the rational design of more potent, highly selective inhibitors against other similar toxins using a totally novel yeast-based approach," says lead author Stagljar. “This innovative approach is an important advance, not only for the value it may have in cystic fibrosis treatment, but also because this technique could be used to design novel therapies for any bacterial pathogen as well as the HIV virus.”

In the next phase of their research, Stagljar and his colleagues plan to test the action of their inhibitors in an animal model of cystic fibrosis. If successful, the therapeutics may provide an avenue for the treatment of this debilitating disease.

Source: University of Toronto

Related stories:

Superbug genome sequenced
The genome of a newly-emerging superbug, commonly known as Steno, has just been sequenced. The results reveal an organism with a remarkable capacity for drug resistance. The research was carried out by scientists at the Wellcome Trust Sanger Institute near Cambridge and the University of Bristol.
Finely tuned WspRs help bacteria beat body by building biofilm
Bacteria are particularly harmful to human health when they band together to form a biofilm—a sheet composed of many individual bacteria glued together—because this can allow them to escape from both antibiotics and the immune system of their host. It is thought that most chronic infections are caused by bacterial biofilms, and a paper published in this week’s PLoS Biology explores the signalling system that causes bacteria to team up in this way.
Bacterial toxin closes gate on immune response
Researchers at the University of Pennsylvania School of Medicine have demonstrated that a bacterial toxin from the common bacterium Staphylococcus aureus shuts down the control mechanism of the tunnel, called an ion channel, in immune cell membranes. Shutting down ion channels has long been known to suppress the immune response, and the bacteria may use the toxin to neutralize host defenses against bacteria. The study is published in the February 14 issue of Nature.
Scientists identify possible target for prevention and treatment of pneumonia
Researchers at Children’s Hospital of Pittsburgh of UPMC have identified a key protein target that may be a crucial factor in the development of a vaccine to prevent and new therapies to treat pneumonia, the leading killer of children worldwide.
Cosmetic products may cause fatal infections in critically ill patients
Healthy consumers can handle the low levels of bacteria occasionally found in cosmetics. But for severely ill patients these bacteria may trigger life-threatening infections, as patients in the intensive care unit at one Barcelona hospital discovered after using contaminated body moisturiser. The Burkholderia cepacia bacteria outbreak is detailed in the open access journal, Critical Care.
CU-Boulder technology used to identify unexpected bacteria in cystic fibrosis patients
Molecular technology developed by a University of Colorado at Boulder professor to probe extreme life forms in undersea hydrothermal vents has been used to identify unexpected bacteria strains in the lung fluid of Denver children suffering from cystic fibrosis, findings that may lead to more effective therapies.
Tiny Silicone Hotel Reveals How Bacteria Control Crowds
Using a device composed of microscopic rooms and hallways that was designed and fabricated at the University of California, San Diego, a team of researchers from four institutions has determined how bacteria self-organize during the early stages of colony formation. The findings may lead to more effective ways to treat or prevent persistent infections.
The bacteria can cheat on their mates
Pursuing our own short term interests by cheating on the rest of the population is not the preserve of the human race. It seems bacteria can operate in just the same way.

News discussion:

Medicine & Health news